Xuedong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuedong Li has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Bosen You
The Second Affiliated Hospital of Harbin Medical University 1 Department of Urology Harbin, China
21 shared publications - Bo Han
The Second Affiliated Hospital of Harbin Medical University 1 Department of Urology Harbin, China
20 shared publications - Dongze Liu
The Second Affiliated Hospital of Harbin Medical University 1 Department of Urology Harbin, China
20 shared publications - Enyang Zhao
The Second Affiliated Hospital of Harbin Medical University 1 Department of Urology Harbin, China
20 shared publications - Jinpeng Wang
The Second Affiliated Hospital of Harbin Medical University 1 Department of Urology Harbin, China
20 shared publications - Jizi Zhao
Heilongjiang Provincial Key Laboratory of Infection and Immunity, Pathogen Biology, Harbin, China
20 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
S. pneumoniae promotes metabolic reprogramming and enhances pazopanib tolerance in ccRCC cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
S. pneumoniae promotes metabolic reprogramming and enhances pazopanib tolerance in ccRCC cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
S. pneumoniae–mediated pazopanib resistance in ccRCC xenografts requires psaA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
S. pneumoniae–mediated pazopanib resistance in ccRCC xenografts requires psaA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Summary of clinical ccRCC patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Summary of clinical ccRCC patients
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
The details of primary antibodies used for western blot, ChIP, immunoprecipitation, immunohistochemistry and immunofluorescence
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
The details of primary antibodies used for western blot, ChIP, immunoprecipitation, immunohistochemistry and immunofluorescence
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
The primers sequences used for ChIP-qPCR
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
The primers sequences used for ChIP-qPCR
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Table S1 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Table S1 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Persistent drug resistance to tyrosine kinase inhibitors (TKI) has become a hurdle in extending the survival of patients with clear cell renal cell carcinoma (ccRCC). Through microbiome screening of patient samples from a ccRCC cohort treated with the TKI pazopanib, we identified Streptococcus pneumoniae as the dominant intratumoral microbiota in pazopanib-resistant ccRCC samples. Further investigation revealed that S. pneumoniae reprogrammed lipid metabolism in ccRCC cells by depleting manganese (Mn2+) from the tumor microenvironment, consequently facilitating malignant progression and development of pazopanib resistance. S. pneumoniae suppressed S-nitrosylation of tripartite motif–containing protein 28 (TRIM28) by diminishing Mn2+ levels, allowing TRIM28 to physically interact with the transcription factor SP1 to promote the transcription of solute carrier family 27 member 1 (SLC27A1) and lipid deposition. Taken together, these findings indicate that tumor-resident S. pneumoniae plays an important role in conferring pazopanib resistance, suggesting that S. pneumoniae could serve as a potential biomarker of pazopanib response in ccRCC.Significance:Streptococcus pneumoniae is an intratumoral bacteria that drives pazopanib resistance in renal cell carcinoma, highlighting the potential of targeting the tumor microbiome as a strategy to improve treatment outcomes in cancer patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Persistent drug resistance to tyrosine kinase inhibitors (TKI) has become a hurdle in extending the survival of patients with clear cell renal cell carcinoma (ccRCC). Through microbiome screening of patient samples from a ccRCC cohort treated with the TKI pazopanib, we identified Streptococcus pneumoniae as the dominant intratumoral microbiota in pazopanib-resistant ccRCC samples. Further investigation revealed that S. pneumoniae reprogrammed lipid metabolism in ccRCC cells by depleting manganese (Mn2+) from the tumor microenvironment, consequently facilitating malignant progression and development of pazopanib resistance. S. pneumoniae suppressed S-nitrosylation of tripartite motif–containing protein 28 (TRIM28) by diminishing Mn2+ levels, allowing TRIM28 to physically interact with the transcription factor SP1 to promote the transcription of solute carrier family 27 member 1 (SLC27A1) and lipid deposition. Taken together, these findings indicate that tumor-resident S. pneumoniae plays an important role in conferring pazopanib resistance, suggesting that S. pneumoniae could serve as a potential biomarker of pazopanib response in ccRCC.Significance:Streptococcus pneumoniae is an intratumoral bacteria that drives pazopanib resistance in renal cell carcinoma, highlighting the potential of targeting the tumor microbiome as a strategy to improve treatment outcomes in cancer patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Fatty acid metabolism-related pathways in GSEA analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Fatty acid metabolism-related pathways in GSEA analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Distinct bacterial community diversity between PAZ-S and PAZ-R samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma
Distinct bacterial community diversity between PAZ-S and PAZ-R samples.